Compare Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 vs GeneDx Holdings Corp — how do they compare? Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $64.59 (market cap $394.18M), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 5.1× Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 for 63 Days and GeneDx Holdings Corp for 19 Days on average.
| SLVO | WGS | |
|---|---|---|
Market Cap | $394.18M | $2.02B |
Volume | 84,843 | 734,640 |
Sector | Income / Options Overlay | Health |
52-Week High | $107.41 | $167.51 |
52-Week Low | $61.81 | $34.51 |
Typical Hold Time | 63 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLVO trades at $64.59, up 1.62% today but remains in a bearish technical trend, with moving averages signaling continued downward pressure. Financial ratios are not available, limiting fundamental clarity. Recent news highlights the stock crossing below its 50-day moving average and links its performance to silver price declines, indicating sensitivity to commodity markets.
The outlook is cautious due to bearish technicals and commodity volatility. Opportunities exist if silver prices stabilize, but risks include dollar strength and lack of fundamental data. Investors should weigh technical recovery potential against macroeconomic headwinds affecting silver.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
